Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1322 - 1334 |
| Number of pages | 13 |
| Journal | Pharmaceuticals |
| Volume | 6 |
| DOIs | |
| Publication status | Published - 2013 |
Cite this
}
Loss of response to long-term infliximab therapy in children with Crohn's disease. / Gouldthorpe, Oliver; Catto-Smith, Anthony; Alex, George; Simpson, Dianne M.
In: Pharmaceuticals, Vol. 6, 2013, p. 1322 - 1334.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Loss of response to long-term infliximab therapy in children with Crohn's disease
AU - Gouldthorpe, Oliver
AU - Catto-Smith, Anthony
AU - Alex, George
AU - Simpson, Dianne M
PY - 2013
Y1 - 2013
N2 - Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth.
AB - Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth.
UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817600/pdf/pharmaceuticals-06-01322.pdf
U2 - 10.3390/ph6101322
DO - 10.3390/ph6101322
M3 - Article
VL - 6
SP - 1322
EP - 1334
JO - Pharmaceuticals
JF - Pharmaceuticals
SN - 1424-8247
ER -